IBRX Latest Headlines

ImmunityBio’s NK-Cell Platform: How IBRX Stands Out in the Race for Next-Gen Cancer Therapy

Market Chameleon (Mon, 8-Jun 9:26 AM)

ImmunityBio Faces Class Action Lawsuit Alleging Misleading Statements About Anktiva Capabilities—What Should Investors Know?

Market Chameleon (Tue, 19-May 10:19 AM)

ImmunityBio’s NAI+BCG Therapy Doubles Complete Response Durability Versus Nadofaragene in Bladder Cancer—New AUA 2026 Data Suggest Clinical Advantage

Market Chameleon (Tue, 19-May 7:54 AM)

IBRX Faces Class Action Lawsuit Amid Ongoing FDA Scrutiny Over Anktiva Drug Promotion

Market Chameleon (Fri, 15-May 11:26 AM)

MiNK Therapeutics Advances iNKT Cell Therapy Platform with Randomized Phase 2 Launch and Broad Clinical Progress

Market Chameleon (Fri, 15-May 7:40 AM)

ImmunityBio's Q1 2026 Revenue Surges 168% Year-over-Year as ANKTIVA Expands Globally

Market Chameleon (Thu, 7-May 8:17 AM)

ImmunityBio Spotlights ANKTIVA's Competitive Edge and Innovation in Bladder Cancer at AUA 2026

Market Chameleon (Tue, 5-May 8:05 AM)